Anti-interleukin-6 therapy in rheumatoid arthritis

Bulletin of the NYU Hospital for Joint Diseases

Volumn 68, Issue 3, 2010, Pages 211-217

  Woodrick, Robert ^a   Ruderman, Eric M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 6; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC PNEUMONITIS; ANAPHYLAXIS; ARTICLE; ASTHMA; CARDIOPULMONARY INSUFFICIENCY; CLINICAL RESEARCH; CLINICAL TRIAL; COLD CLAMMY SKIN; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMOPHAGOCYTOSIS SYNDROME; HUMAN; HYPERLIPIDEMIA; LEG INFECTION; MONOTHERAPY; NEUTROPENIA; OSTEOMYELITIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPTICEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; INTERLEUKIN-6; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78449263222     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatorycytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997 Mar;24(3):518-23.
2. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheu-matology (Oxford). 1999 Mar;38(3):202-13.
3. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990 May 1;144(9):3347-53.
4. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29. Epub 2006 Jan 6.
5. Hyrich KL, Lunt M, Watson KD, et al. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheu-matoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56:13-20.
6. Nuki G, Bresnihan B, Bear MB, McCabe D; European Group Of Clinical Investigators. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov;46(11):2838-46.
7. Sack U, Kinne RW, Marx T, et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45-51.
8. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin-6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993 Mar;52(3):232-4.
9. Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999 Aug;42(8):1635-43.
10. Hata H, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-alpha, IL-1 and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice J Clin Invest. 2004 Aug;114(4):582-8.
11. Poli V, Maritano D. IL-6 Knockout mice. In: Fantuzzi G (ed): Cytokine Knockouts. Totowa, New Jersey: Humana Press, 2003, pp. 213-234.
12. Mihara M, Kotoh M, Nishimoto N, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol. 2001 Mar;98(3):319-26.
13. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL6-R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005 Nov;5(12):1731-40.
14. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 2002 Dec;46(12):3143-50.
15. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2004 Jun;50(6):1761-9.
16. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. nn Rheum Dis. 2007 Sep;66(9):1162-7; Epub 2007 May 7.
17. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical control trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006 Sep;54(9):2817-29. Erratum in: Arthritis Rheum. 2008 Mar;58(3):887.
18. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008 Mar 22;371(9617):987-97.
19. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologics: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis. 2008 Nov;67(11):1516-23; Epub 2008 Jul 14. Erratum in: Ann Rheum Dis. 2009 Feb;68(2):296.
20. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008 Oct;58(10):2968-80.
21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010 Jan;69(1):88-96.